Update in 68Ga-PSMA PET/CT Reporting





Prepared By:

- Maghsudi Mehdi, MD, Nuclear Medicine Physician
- · Amini Hamidreza, MD, Nuclear Medicine Physician
- . Divband GhasemAli, MD, Nuclear Medicine Physician

Staging:

EUROPEAN UROLOGY 83 (2023) 405-412

available at www.sciencedirect.com journal homepage: www.europeanurology.com





Review - Prostate Cancer


Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)

Whole-body miTNM staging system for standardized PSMA-PET interpretation

| Local tumor (T) | | | | | | |
|-----------------------|-----|--|---|--|--|--|
| miT0 | | No local tumor | | | | |
| miT2 | | Organ-confined tumor | 30 | | | |
| | u | Unifocality | H WIENTER | | | |
| 1 | m | Multifocality | 36 30 | | | |
| miT3 | PE | Non-organ-confined tumor | PEI | | | |
| | а | Extracapsular extension | | | | |
| | b | Tumor invades seminal vesicle(s) | | | | |
| miT4 | | Tumor invades adjacent structures other than seminal vesicles, such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall | | | | |
| miTr | | Presence of local recurrence after radical prostatectomy | TA JULY TER | | | |
| Intrapelvic nodes (N) | | | | | | |
| miN0 | | No positive pelvic lymph nodes | PET | | | |
| miN1 | | Single lymph node region harbors lymph node metastases, report location by a standardized template Multiple (22) lymph node regions harbor lymph node metastases, | Lymph node regions: Il internal iliac, laterality (L/R) El external iliac, laterality (L/R) OB obturator, laterality (L/R) PS presacral OP other pelvic | | | |
| miN2 | | report location(s) by a standardized template | | | | |
| Distant metastasis | S | | 300 | | | |
| miM0 | bp, | No distant metastasis | PE | | | |
| miMl | | Distant metastasis | | | | |
| | а | Distant lymph node region(s) | miMla regions: CI common iliac, laterality (L/R) RP retroperitoneal SD supradiaphragmatic OE inguinal and other extrapelvic | | | |
| | b | Bone(s), additionally report pattern and involved bone(s) in case of unifocal or oligometastatic | Bone uptake patterns: uni unifocal oligo oligometastatic (n ≤ 3) diss disseminated dmi diffuse marrow involvement | | | |
| | С | Other site(s), additionally report involved organ (hep, pul, adrenal, peritoneal invasion | brain, other). Other includes pleural o | | | |


PSMA-PET = prostate-specific membrane antigen targeting positron emission tomography.








Regional lymph node metastases (N) miN1 = single pelvic region involved miN2 = two or more pelvic regions involved



Locations:

- I Internal iliac (II) left/right
- II External iliac (EI) left/right
- III Obturator (OB)
- IV Presacral (PS)
- V Other pelvic (OP)



Diagnosis (+ Staging) of Prostate Cancer:




Research Article | Clinical Investigation

Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database

Louise Emmett, Nathan Papa, William Counter, Jeremie Calais, Francesco Barbato, Irene Burger, Matthias Eiber, Matthew J. Roberts, Shikha Agrawal, Anthony Franklin, Alan Xue, Krishan Rasiah, Nikeith John, Daniel Moon, Mark Frydenberg, John Yaxley, Phillip Stricker, Keith Wong, Geoff Coughlin, Troy Gianduzzo, Boon Kua, Bao Ho, Andrew Nguyen, Victor Liu, Jonathan Lee, Edward Hsiao, Tom Sutherland, Elisa Perry, Wolfgang P. Fendler and Thomas A. Hope
Journal of Nuclear Medicine January 2024, 65 (1) 94-99; DOI: https://doi.org/10.2967/jnumed.123.266164


PRIMARY Score Definition



Diagnostic Accuracy for PI-RADS from mpMRI, PRIMARY from PSMA PET, and Combination

| Parameter | Sensitivity | Specificity | Positive predictive value | Negative predictive value |
|-------------|---------------|----------------|---------------------------|---------------------------|
| PRIMARY | 86% (79%-91%) | 76% (64%-85%) | 88% (82%-93%) | 72% (61%-81%), |
| PI-RADS | 89% (83%-93%) | 74% (63%-84%) | 88% (82%-93% | 76% (65%-86%) |
| Combination | 94% (89%-97%) | 68% (56%-78%). | 86% (80%-91%) | 85% (73%-93%) |


Association between PSMA PET SUVmax and ISUP grade group



Patient 1:

A -65year-old patient with PSA level of 34.5 ng/mL was diagnosed with ISUP Gleason Grade Group 3 prostate cancer. Subsequent PSMA-PET/CT showed a singular pararectal lymph node metastasis. MIP (A) and axial CT, PET and fused images demonstrate high PSMA-ligand uptake of the primary tumor (B-D) and a single lymph node metastasis (E-G).


PROMISE code: miT2m N1(OP) M0, PRIMARY5, PSMA expression score lowest and highest 3



Patient 2:

A -76year-old patient underwent PSMA-PET/CT to determine PSMA-expression prior to ¹⁷⁷Lu-PSMA therapy. The patient was initially diagnosed with ISUP Gleason Grade Group 5 prostate cancer showing synchronous metastatic disease in the lymph nodes and bone with high tumor volume according to CHAARTED. He was primarily treated with androgen deprivation therapy and with docetaxel. After castration-resistance, the patient was treated with abiraterone and subsequently with cabazitaxel. MIP (A) and axial images (B-D) show lymph node and bone metastases with PSMA uptake higher than liver.


PROMISE code: miT0 N2 M1a 1b (diss), PSMA expression score lowest 2 and highest 3



Patient 3:

A -72year-old patient developed biochemical recurrence 1 year after radical prostatectomy of locally advanced ISUP Gleason Grade Group 5 prostate cancer. PSMA-PET/CT showed oligometastatic disease with a single bone metastasis in the pelvis with intense PSMA uptake shown in the MIP (A) and the axial images (B-D).

PROMISE code: miTO NO M1b (uni), PSMA expression score lowest and highest 3



References:

- 1. Seifert R, Emmett L, Rowe SP, Herrmann K, Hadaschik B, Calais J, Giesel FL, Reiter R, Maurer T, Heck M, Gafita A. Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2). European Urology. 2023 May 12-405:(5)83;1.
- 2. Emmett L, Papa N, Counter W, Calais J, Barbato F, Burger I, Eiber M, Roberts MJ, Agrawal S, Franklin A, Xue A. Reproducibility and accuracy of the PRIMARY score on PSMA PET and of PI-RADS on multiparametric MRI for prostate cancer diagnosis within a real-world database. Journal of Nuclear Medicine. 2024 Jan 9-94:(1)65;1.





KHATAM PET / CT CENTER www.petctkhatam.ir



خط ویژه: ۲۱-۹۲۰۰۲۲۰۲



info@petctkhatam.ir www.petctkhatam.ir @ petct.khatam



خیابان ولیعصر (عج)، بالاتر از میرداماد، خیابان(شیدیاسعی، جنب بیمارستان خاتم الانبیاء (ص)، ساختمان یاس، طبقه همکف